Comerica Bank Increased Accenture Plc Cl A (ACN) Stake By $1.52 Million; 6 Bullish Analysts Covering Ironwood Pharmaceuticals, Inc. (IRWD)

June 22, 2018 - By Peter Erickson

Accenture plc (NYSE:ACN) Logo

Among 16 analysts covering Ironwood Pharmaceuticals (NASDAQ:IRWD), 6 have Buy rating, 3 Sell and 7 Hold. Therefore 38% are positive. Ironwood Pharmaceuticals had 44 analyst reports since August 6, 2015 according to SRatingsIntel. As per Friday, February 19, the company rating was maintained by Barclays Capital. Wedbush maintained it with “Neutral” rating and $10 target in Thursday, April 28 report. The rating was maintained by Mizuho with “Buy” on Tuesday, May 10. Barclays Capital maintained the shares of IRWD in report on Wednesday, February 22 with “Equal Weight” rating. Wedbush maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) rating on Friday, February 19. Wedbush has “Neutral” rating and $9 target. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, October 10 with “Buy” rating. As per Tuesday, September 27, the company rating was maintained by WallachBeth Capital. The firm has “Neutral” rating given on Monday, March 21 by Goldman Sachs. On Friday, January 5 the stock rating was downgraded by Bank of America to “Sell”. Mizuho maintained Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Friday, October 6 with “Buy” rating. See Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) latest ratings:

31/05/2018 Broker: Mizuho Rating: Buy New Target: $24.0000 Maintain
31/05/2018 Broker: Wells Fargo Old Rating: Outperform New Rating: Outperform Old Target: $18 New Target: $20 Maintain
09/05/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Downgrade
02/05/2018 Broker: Barclays Capital Rating: Hold New Target: $20.0000
02/05/2018 Broker: Mizuho Old Rating: Neutral New Rating: Buy Upgrade
19/04/2018 Broker: Berenberg Rating: Buy New Target: $25.0000 Initiate
12/03/2018 Broker: Mizuho Rating: Hold New Target: $16.0 Maintain
09/01/2018 Broker: Mizuho Rating: Hold New Target: $16.0 Maintain
05/01/2018 Broker: Bank of America Rating: Sell New Target: $15.0 Downgrade

Comerica Bank increased Accenture Plc Cl A (ACN) stake by 5.75% reported in 2018Q1 SEC filing. Comerica Bank acquired 9,892 shares as Accenture Plc Cl A (ACN)’s stock declined 5.31%. The Comerica Bank holds 181,839 shares with $28.11 million value, up from 171,947 last quarter. Accenture Plc Cl A now has $102.35 billion valuation. The stock decreased 0.55% or $0.877 during the last trading session, reaching $159.153. About 502,613 shares traded. Accenture plc (NYSE:ACN) has risen 26.72% since June 22, 2017 and is uptrending. It has outperformed by 14.15% the S&P500. Some Historical ACN News: 29/03/2018 – Tinker Federal Credit Union Selects Mortgage Cadence as Best-In-Class Technology Partner; 09/03/2018 – TOYOTA MOTOR CORP – THE COMPANIES COLLECT TAXI SERVICE LOG DATA AND DEMOGRAPHIC PREDICTIONS AS WELL AS OTHER FACTORS THAT AFFECT TAXI DEMAND; 12/04/2018 – Accenture Appoints Venkata “Murthy” Renduchintala, Executive Officer at Intel, to Board of Directors; 20/03/2018 – SAP SE SAPG.DE – ACCENTURE AND SAP TO BUILD AND DEPLOY EXTENDED PLANNING SOLUTIONS ON SAP S/4HANA; 21/05/2018 – Accenture Awarded U.S. Patent for ZBx Al Platform that Categorizes Data for Zero-Based Spend Analysis; 03/05/2018 – Accenture to Co-Develop Digital Defense and Security Solution with SAP, Helping Defense Agencies Accelerate Digital; 22/03/2018 – ACCENTURE CEO – FOR THE FIRST HALF OF FISCAL ’18, REVENUE FROM “THE NEW” WAS NEARLY $11 BLN, MORE THAN 55 PCT OF TOTAL REVENUE – CONF CALL; 13/03/2018 – Accenture Appoints Vukani Mngxati Country Managing Director for South Africa; 31/05/2018 – OpenX Appoints Accenture Executive Roxanne Taylor to Board of Directors; 11/04/2018 – Accenture Launches Intelligent Enterprise Platform to Help Companies Use Advanced Technologies that Fast-track Enterprise

Investors sentiment increased to 0.97 in Q1 2018. Its up 0.04, from 0.93 in 2017Q4. It is positive, as 50 investors sold ACN shares while 396 reduced holdings. 105 funds opened positions while 326 raised stakes. 449.75 million shares or 1.56% less from 456.89 million shares in 2017Q4 were reported. Kayne Anderson Rudnick Inv Mgmt Lc invested 0.25% of its portfolio in Accenture plc (NYSE:ACN). Financial Architects, New Jersey-based fund reported 2,535 shares. 2,900 are owned by First Pacific Advisors Ltd. Delta Asset Mgmt Ltd Tn holds 0% of its portfolio in Accenture plc (NYSE:ACN) for 107 shares. Welch & Forbes Lc stated it has 0.01% in Accenture plc (NYSE:ACN). Lowe Brockenbrough has 0.12% invested in Accenture plc (NYSE:ACN) for 5,386 shares. Epoch Inv Prtn Inc holds 72,555 shares or 0.04% of its portfolio. Bp Public Ltd reported 78,000 shares. Amp Invsts accumulated 0.22% or 262,516 shares. Troy Asset Management holds 0.1% in Accenture plc (NYSE:ACN) or 16,500 shares. Amica Retiree Medical Trust has invested 0.53% in Accenture plc (NYSE:ACN). Howe And Rusling holds 933 shares or 0.03% of its portfolio. Cooke Bieler Lp holds 0.72% or 250,837 shares in its portfolio. Jennison Assoc Ltd Limited Liability Company holds 0% or 25,416 shares in its portfolio. Wellington Mngmt Grp Ltd Liability Partnership invested in 15.66 million shares.

Among 26 analysts covering Accenture Plc (NYSE:ACN), 16 have Buy rating, 1 Sell and 9 Hold. Therefore 62% are positive. Accenture Plc had 99 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Accenture plc (NYSE:ACN) earned “Hold” rating by SunTrust on Wednesday, May 24. As per Wednesday, September 28, the company rating was maintained by Citigroup. The firm has “Hold” rating given on Thursday, September 21 by Robert W. Baird. The stock of Accenture plc (NYSE:ACN) has “Hold” rating given on Friday, March 24 by BMO Capital Markets. The firm has “Buy” rating given on Thursday, November 2 by Stifel Nicolaus. Deutsche Bank maintained Accenture plc (NYSE:ACN) on Monday, March 27 with “” rating. On Monday, August 14 the stock rating was maintained by RBC Capital Markets with “Buy”. Stifel Nicolaus maintained the shares of ACN in report on Monday, March 21 with “Buy” rating. Wedbush maintained Accenture plc (NYSE:ACN) on Monday, April 2 with “Buy” rating. The stock has “Equal-Weight” rating by Barclays Capital on Friday, September 30.

Comerica Bank decreased Sm Energy Co (NYSE:SM) stake by 25,148 shares to 91,419 valued at $1.99M in 2018Q1. It also reduced Dollar Tree Inc (NASDAQ:DLTR) stake by 3,549 shares and now owns 106,884 shares. Verisk Analytics Inc Cl A (NASDAQ:VRSK) was reduced too.

More news for Accenture plc (NYSE:ACN) were recently published by: Streetinsider.com, which released: “Cowen Reiterates Outperform on Accenture (ACN) Ahead of 3Q Release” on June 22, 2018. Gurufocus.com‘s article titled: “3 IT Stocks to Consider Amid Worries Over Trade” and published on June 21, 2018 is yet another important article.

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company has market cap of $2.84 billion. The firm markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It currently has negative earnings. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan.

The stock increased 0.48% or $0.09 during the last trading session, reaching $18.7. About 154,235 shares traded. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has declined 9.49% since June 22, 2017 and is downtrending. It has underperformed by 22.06% the S&P500. Some Historical IRWD News: 01/05/2018 – Under pressure, Peter Hecht splits Ironwood into two biotechs, spinning out an R&D operation $IRWD; 01/05/2018 – Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to; 06/04/2018 – FBO:Veteran Aff: Veterans Affairs Contract Award – 65–Ironwood Pharmaceuticals, Inc (65IB) New Contract Effective: 5/1/2018 to; 31/05/2018 – SARISSA CAPITAL – BELIEVE PLAN TO SEPARATE IRONWOOD’S R&D PROGRAMS FROM COMMERCIAL BUSINESS IS “GOOD FIRST STEP” TOWARD CREATING SHAREHOLDER VALUE; 14/05/2018 – Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees; 03/05/2018 – lronwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation; 03/05/2018 – ALLERGAN – SETTLEMENT WITH AUROBINDO IS SECOND PATENT INFRINGEMENT SETTLEMENT COMPANIES HAVE REACHED WITH RESPECT TO LINZESS; 09/04/2018 – Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital; 09/04/2018 – IRONWOOD PHARMACEUTICALS REPORTS DIRECTOR NOMINATION FROM SARIS; 01/05/2018 – IRONWOOD PHARMACEUTICALS PROVIDES 1Q 2018 INVESTOR UPDATE

Investors sentiment decreased to 0.7 in Q1 2018. Its down 0.35, from 1.05 in 2017Q4. It worsened, as 20 investors sold Ironwood Pharmaceuticals, Inc. shares while 50 reduced holdings. 19 funds opened positions while 30 raised stakes. 150.40 million shares or 0.28% more from 149.98 million shares in 2017Q4 were reported. Glenmede Na reported 2,110 shares. Alps Advisors has invested 0.02% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Public Employees Retirement Association Of Colorado holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 24,883 shares. Fifth Third Bancshares holds 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 2,130 shares. Engineers Gate Manager Limited Partnership owns 111,861 shares for 0.12% of their portfolio. Bailard accumulated 23,000 shares or 0.02% of the stock. Park West Asset Management Limited Liability Corp, California-based fund reported 630,593 shares. Ameritas Prtnrs has 0.01% invested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) for 11,821 shares. Trexquant Investment L P holds 0.07% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) or 61,559 shares. Plante Moran Financial Advsr Ltd Com owns 122 shares. Manufacturers Life Insurance Com The has invested 0% in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Balyasny Asset Mgmt Ltd Limited Liability Company stated it has 0% of its portfolio in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD). Citadel Advisors Lc holds 245,195 shares or 0% of its portfolio. Ww accumulated 2.03M shares or 0.01% of the stock. Hemenway Tru Commerce Limited Liability Co invested in 13,630 shares or 0.04% of the stock.

Since January 24, 2018, it had 0 buys, and 9 selling transactions for $1.28 million activity. MCCOURT Thomas A also sold $49,008 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares. 7,741 shares valued at $113,483 were sold by Gilbert Halley E on Wednesday, February 21. OLANOFF LAWRENCE S also sold $28,100 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Monday, March 5. $52,688 worth of stock was sold by Consylman Gina on Wednesday, February 21. $26,430 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was sold by McHugh Julie. Currie Mark G also sold $927,000 worth of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) on Wednesday, January 24.

More important recent Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) news were published by: Seekingalpha.com which released: “Ironwood launches late-stage program for IW-3718 in GERD” on June 21, 2018, also Streetinsider.com published article titled: “Ironwood Pharma (IRWD) Commences Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux …”, Businesswire.com published: “Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease” on June 21, 2018. More interesting news about Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) was released by: Streetinsider.com and their article: “Ironwood Pharma (IRWD) Announces FDA Orphan Drug Designation for Olinciguat for Treatment of Sickle Cell Disease” with publication date: June 07, 2018.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.